Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × durvalumab × 90 days × Clear all

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 38 Lung Neoplasms 25 Small Cell Lung Carcinoma 18 Carcinoma, Hepatocellular 18 Urinary Bladder Neoplasms 10 Liver Neoplasms 9 Biliary Tract Neoplasms 9 Neoplasms 6 Stomach Neoplasms 5 Cholangiocarcinoma 5 Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Ovarian Neoplasms 4 Carcinoma 4 Triple Negative Breast Neoplasms 3 Respiratory Tract Neoplasms 3 Neoplasms by Site 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Transitional Cell 3 Adenocarcinoma 3 Uterine Cervical Neoplasms 2 Thoracic Neoplasms 2 Respiratory Tract Diseases 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Oropharyngeal Neoplasms 2 Neoplasm Metastasis 2 Mouth Neoplasms 2 Mesothelioma, Malignant 2

Interventions

Cyclophosphamide 5 fludarabine 4 Dexamethasone 4 blinatumomab 3 Lenalidomide 3 pembrolizumab 2 fludarabine phosphate 2 Cytarabine 2 venetoclax 1 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 tagraxofusp 1 relugolix 1 obinutuzumab 1 nilotinib 1 ixazomib 1 isatuximab 1 inavolisib 1 giredestrant 1 enzalutamide 1 daratumumab 1 abemaciclib 1 Vincristine 1 Transplantation 1 Radiotherapy 1 Neoadjuvant Therapy 1 Monatide (IMS 3015) 1 Methotrexate 1 Melphalan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡